Halberd Corporation (OTCMKTS: HALB) has announced a potentially game-changing technique for removing disease-causing antigen(s) that does not rely on metallic nanoparticles attached to antibodies.
New disease-causing antigens removal technique uses available equipment in hospitals.
This more straightforward technique for removing disease-causing antigen(s) makes use of more standard medical equipment available in clinics and hospitals, as well as our patented extracorporeal therapy technique. The strategy is expected to streamline the commercial stocking and distribution of treatment components while also lowering treatment administration expenses.
The company’s CEO, President, and Chairman, William A. Hartman, said, “This simplified treatment process will be developed simultaneously with the radio frequency & laser emissive energy concepts. Halberd will initially target this process for application to the treatment of Alzheimer’s Disease, which will involve three peptide/protein antigens – tau, phosphorylated tau, & beta amyloid – plus four inflammatory cytokines linked to the development and progression of Alzheimer’s Disease.”
Harman added that details are pending as the company prepares a provisional patent as development work goes on. He said they are excited about the concept considering it minimizes cost and development time, providing enhanced market acceptability and more possible commercial opportunities for the company.
Halberd Corporation conjugates metallic particles successfully against antigens.
Recently the company announced that it successfully conjugated Phosphorylated Tau, Beta-amyloid, and Tau antibodies through gold-coated iron oxide nanoparticles in a pending patent process. The three antigens were present in Cerebral Spinal Fluid (CFS) and related to neurofibrillary tangles associated with AD formation. The conjugation of the antibodies with metallic particles offers an extracorporeal removal of the AD-associated antigens from CFS via exposures to laser emissive energy of tuned radio frequency.
GreenBioAz’s Dr. Shawn Q. Chen and his team are leading the study.
